Who
Paul K. Wotton
Director
Company insider
Files Form 4 as: Director, Vericel; President and CEO, Ocata Therapeutics; President and CEO, Antares Pharma; Director, Genaera.
In numbers
- Trades disclosed
- 147
- Buys
- 3
- Sells
- 21
- Bought
- $35K
- Sold
- $4.7M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 3 Jan 2006
- Last trade
- 11 May 2026
- Last filed
- 13 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 May 2026filed 13 May 2026 | VCEL VericelBiotechnology | SEC FORM 4 Sold | $83K2,500 at $33.05 | filing |
| 11 May 2026filed 13 May 2026 | VCEL VericelBiotechnology | SEC FORM 4 Sold | $245K7,500 at $32.64 | filing |
| 11 May 2026filed 13 May 2026 | VCEL VericelBiotechnology | SEC FORM 4 Sold | $83K2,500 at $33.05 | filing |
| 11 May 2026filed 13 May 2026 | VCEL VericelBiotechnology | SEC FORM 4 Sold | $245K7,500 at $32.64 | filing |
| 29 Apr 2026filed 1 May 2026 | VCEL VericelBiotechnology | SEC FORM 4 Code M | —3,200 | filing |
| 29 Apr 2026filed 1 May 2026 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code M | —3,200 | filing |
| 29 Apr 2026filed 1 May 2026 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 29 Apr 2026filed 1 May 2026 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code M | —3,200 | filing |
| 29 Apr 2026filed 1 May 2026 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 29 Apr 2026filed 1 May 2026 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code A | —3,200 at $0.00 | filing |
| 29 Apr 2026filed 1 May 2026 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code A | —3,200 at $0.00 | filing |
| 29 Apr 2026filed 1 May 2026 | VCEL VericelBiotechnology | SEC FORM 4 Code M | —3,200 | filing |
| 3 Dec 2025filed 4 Dec 2025 | VCEL VericelBiotechnology | SEC FORM 4 Sold | $95K2,500 at $37.83 | filing |
| 2 Dec 2025filed 4 Dec 2025 | VCEL VericelBiotechnology | SEC FORM 4 Sold | $95K2,500 at $37.97 | filing |
| 30 Apr 2025filed 2 May 2025 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code M | —3,200 at $0.00 | filing |
| 30 Apr 2025filed 2 May 2025 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 30 Apr 2025filed 2 May 2025 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code A | —3,200 at $0.00 | filing |
| 30 Apr 2025filed 2 May 2025 | VCEL VericelBiotechnology | SEC FORM 4 Code M | —3,200 | filing |
| 4 Dec 2024filed 5 Dec 2024 | VCEL VericelBiotechnology | SEC FORM 4 Sold | $153K2,600 at $58.72 | filing |
| 1 May 2024filed 3 May 2024 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code M | —3,200 | filing |
News
No headline names them, or the companies they trade most, lately.